Drug intelligence / Profile preview

Bifidobacterium bifidum + 2'-fucosyllactose

Development stage
Preclinical
Lead developer
Chang Gung Memorial Hospital
Modality
Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration
Oral
01

Overview

Bifidobacterium bifidum + 2'-fucosyllactose is a synbiotic combination product consisting of the probiotic bacterium *Bifidobacterium bifidum* and the prebiotic 2'-fucosyllactose (2'-FL). [1, 2] *B. bifidum* is a beneficial microbe naturally found in the human gastrointestinal tract, particularly in healthy, breastfed infants. [15, 18] 2'-FL is the most abundant human milk oligosaccharide (HMO), a complex sugar that is indigestible by humans but serves as a selective nutrient for specific gut bacteria. [2, 5, 18] The synergistic mechanism involves 2'-FL promoting the growth, gut adhesion, and proliferation of *B. bifidum*. [1, 3, 6] This modulation of the gut microbiome enhances intestinal barrier function, helps competitively exclude pathogens, and produces beneficial metabolites like short-chain fatty acids (SCFAs). [1, 13, 15] This combination is primarily used in infant formulas to mimic the bifidogenic effect of breast milk and as a dietary supplement to support digestive health. [12, 21] Studies have investigated its potential benefits for conditions such as constipation, irritable bowel syndrome (IBS), and immune system modulation. [1, 11]

Other names
Bifidobacterium bifidum and 2'-FL两歧双歧杆菌 + 2′-FL
02

Targets

Bifidobacterium bifidum

Beyond the preview

Go deeper on Bifidobacterium bifidum + 2'-fucosyllactose.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bifidobacterium bifidum + 2'-fucosyllactose.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call